Marco's Morning Report — Monday, July 27, 2026

Morning, Marco — hope the night was survivable. Two things actually matter for your admissions today, and they're both sitting in the CDC's outbreak column: the largest Cyclospora outbreak ever recorded in the U.S. keeps growing, and a separate Salmonella egg recall is running alongside it. Overseas, a second straight day without U.S.–Iran strikes pulled crude off the boil. And the new lipid guideline has turned into a genuine fight worth reading — that's today's Debate. Coffee, then bed.

A · Top Stories

Cyclospora outbreak is now the largest ever recorded in the U.S. — 1,947 cases, 9 states, 98 hospitalized

CDC / FDAFresh CDC's latest investigation update pushed the Taco Bell–linked cyclosporiasis outbreak to 1,947 confirmed infections across 9 states, adding Illinois, Kansas, Oklahoma and Pennsylvania since the July 18 update. Source is shredded iceberg lettuce from Taylor Farms de México, recalled July 17. Illness onsets run June 22 through July 20 — so the tail is still live, and a second, unrelated Cyclospora cluster is now under investigation. CDC investigation update · FDA traceback

Why it matters to you: Cyclospora is the parasite that hides from your standard workup. Routine stool culture won't find it, and it's frequently missed on conventional O&P unless someone specifically asks for modified acid-fast staining or a GI PCR panel that includes C. cayetanensis. The clinical picture — watery diarrhea for weeks, profound fatigue, anorexia, weight loss, relapsing course — is exactly the elderly patient who lands on your service dehydrated with an AKI and a "failure to thrive" tag. Treatment is TMP-SMX; there's no useful alternative for sulfa-allergic patients, which is a real problem in your population. Reporting lag is up to six weeks, so the true count is higher than 1,947.

Tonight: On any admission with ≥3 days of watery diarrhea since mid-June, ask the Taco Bell / bagged-lettuce question explicitly and order the GI panel rather than a plain O&P. Worth a two-line note to your ED colleagues and the ID pharmacist — TMP-SMX dosing in CKD is where this one goes sideways.

Second CDC foodborne outbreak running concurrently: Salmonella Enteritidis in shell eggs, 1.59 million dozen recalled

CDC / FDAFresh Midwest Poultry Services recalled 1,589,577 dozen white and brown cage-free shell eggs distributed from Texas farms between June 6 and July 3, with sell-by dates running through August 17. Case count stands at 98 across 17 states with 26 hospitalizations — a 27% hospitalization rate, which is high. Florida is not yet on the state list, but neighboring Georgia is. CDC update · FDA recall detail

Why it matters to you: The 26/98 hospitalization ratio is the tell — this serotype is landing hard in exactly the demographic you admit. In adults over 65, nontyphoidal Salmonella carries meaningfully elevated risk of bacteremia and endovascular seeding, and anyone with an AAA, a prosthetic valve, or a stent deserves blood cultures rather than a symptomatic-care discharge. Recall dates run through mid-August, meaning contaminated cartons are still sitting in home refrigerators right now.

Practical: For febrile elderly gastroenteritis this week, draw blood cultures before you decide on disposition. Antibiotics still aren't indicated for uncomplicated cases — but "uncomplicated" is a harder call at 78 with a graft.

Update: second straight day with no U.S.–Iran strikes; crude falls back toward $83

Al JazeeraUpdate The pause held for a second consecutive day, with Qatar and Pakistan shuttling messages between Washington and Tehran. Iran's foreign ministry spokesman Esmaeil Baghaei confirmed the mediation on Austrian broadcaster ORF while noting that past diplomacy had been "betrayed." Crude slid toward $83/bbl Monday — down sharply from last week's $100+ — though gasoline is still hovering near $4.00/gal, and the month is up roughly 18%. The unresolved sticking point remains commercial shipping through Hormuz. Al Jazeera · Mediation analysis

Why it matters to you: The supply-chain anxiety of the last two weeks — IV fluids, injectables, anything petroleum-derived in the sterile supply chain — eases if this holds past midweek. It's a pause, not a settlement; the MoU is still voided and Hormuz is still contested.

Talking point: If your group has been sitting on a contingency conversation about single-source injectables, this is the window to have it calmly rather than in a shortage.

B · The Debate

Should more than half of American adults be on a statin?

Why it's live right now: The 2026 ACC/AHA multisociety dyslipidemia guideline extended risk assessment to ages 30–79 and shifted it from a 10-year to a 30-year horizon. A University of Pittsburgh analysis published last week put the arithmetic on the table — 87.5 million U.S. adults (56.6%) now statin-eligible, 21.5 million of them newly so, and 93% of people in their 70s. That number lit the fuse, and the guideline's own writing committee has since published a formal rebuttal to its loudest critic.

The case FOR

Members of the ACC/AHA writing committee, in Medscape; Timothy S. Anderson, MD (Univ. of Pittsburgh), in TCTMD

Atherosclerosis is a decades-long disease and a 10-year risk window was always an artifact of trial length, not biology. A 52-year-old with a 2% ten-year risk and a 15% thirty-year risk is not low-risk — she is early-risk, and the drug that helps her is generic, cheap, and among the best-characterized molecules in medicine. The committee points to DANCAVAS, which showed an 11% relative reduction in all-cause mortality, and argues that coronary-calcium-guided initiation actually resulted in fewer statin starts and lower estimated costs than blanket risk-score prescribing. Anderson frames the change as a shift in the conversation rather than a mandate: "The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients." Eligibility, on this reading, is the opening of a shared decision — not an automatic prescription.

"In Defense of the 2026 Dyslipidemia Guideline" (Medscape) · Anderson in TCTMD

The case AGAINST

John Mandrola, MD, electrophysiologist and Medscape columnist; NLA/AGS expert consensus (Ariela Orkaby, MD, et al.)

A guideline that makes most of the adult population eligible for a drug should rest on unusually strong evidence, and this one does not. Mandrola's objection is procedural before it is clinical: too many Class I recommendations without randomized support, no independent systematic review of prespecified questions, an "extensive evidence review" whose search strategy and inclusion criteria were never disclosed, minimal primary-care representation on the committee, no consideration of patient treatment preferences, and intellectual conflicts of interest running through the panel. The thirty-year risk model compounds the problem — it rests on estimated rather than measured LDL-C and on an eGFR that misclassifies people whose muscle mass doesn't match the average patient. For older adults the separate NLA/AGS consensus is blunter still: direct randomized evidence above 75 is thin, ALLHAT-LLT post-hoc analysis showed no benefit and a hint of harm, and time-to-benefit runs about 2.5 years — which is a long time to wait when life expectancy is the limiting variable.

Mandrola, "Grading the New Dyslipidemia Guidelines" · "Lipid Guidelines: Four Major Concerns" · NLA/AGS consensus on adults >75

Where it might land: Watch whether the quality measures follow the guideline. The moment statin eligibility becomes a scored performance metric, the shared-decision framing the committee is leaning on stops doing any real work.

C · On My Radar

Mets — Soto's calf is worse than Friday looked. Grade 2 left calf strain, 10-day IL, and interim manager Andy Green says at least three weeks, probably more. Eric Wagaman up from Syracuse. At 43-61 with the deadline eight days out, this removes any last argument for a half-measure. ESPN

Mets deadline board. Freddy Peralta (impending FA, extension talks described as virtually nonexistent), Clay Holmes, A.J. Minter, Brooks Raley, Luke Weaver all in play; Brett Baty framed as the most desirable change-of-scenery piece. Deadline is Monday, Aug 3, 6 p.m. ET. MLBTR

Puerto Rico — heat and fire, not storms. NWS San Juan ran another island heat advisory this weekend. LUMA says wildfires driven by drought and heat have hit transmission infrastructure in Sabana Grande and Ciales, and it is leaning on Customer Battery Energy Sharing — now 90,000+ customers contributing an average 75 MW — to blunt peak-demand shortfalls. LUMA

Cuba — Moncada at 73, delivered from Pinar del Río. Díaz-Canel told a 5,000-person crowd Sunday that Cuba is "waging a historic battle against the walls of a genocidal policy," opened with a message from Raúl Castro, and framed 2026 as the centenary of Fidel's birth. The operative line was the closing one — seek alternatives, conserve every resource "as if it were the last," produce, substitute imports. Delivered against five total grid collapses so far this year. Cubadebate · La Jornada

Golf tech — the photometric side answers back. Square Golf's Omni Edition ($1,600) is a four-camera photometric unit that finally works outdoors on grass, and adds the two metrics the original Square was missing: clubhead speed and smash factor. That fixes the one thing that made the cheaper photometric units unusable for anything but indoor ball-flight. PlayBetter

Movies & TV. Man on the Run, the Paul McCartney documentary, is holding as the critics' pick — "a lovely testament to the musical genius and his romantic partnership with Linda." The Serpent's Skin is the interesting one: a feel-good horror hybrid getting real praise for narrative ingenuity. Silo S3 and The Vampire Lestat both landing well. RT best new movies

FY2027 IPPS final rule still pending. As of this morning the April proposed rule (net +2.4%, ~$1.9B, 3.2% market basket less 0.8 productivity) has not been finalized. Historically it drops the first days of August — so expect it inside the next two weeks, alongside the DSH/uncompensated-care methodology change and the GME requirements. CMS fact sheet

D · Trends to Watch

Produce-borne parasites are outrunning the diagnostic default. Two simultaneous multistate outbreaks — one parasitic, one bacterial — both traced to items that never see heat before service. Cyclospora in particular exposes a structural gap: hospitals that still run "stool culture + O&P" as the reflex order set will keep missing it, and the six-week reporting lag means the epidemiology always arrives after the admission. The move toward multiplex GI PCR as the first-line order isn't a cost question anymore; it's a diagnostic-accuracy question.

Guideline legitimacy is becoming its own fight. The lipid argument is nominally about statins but actually about process — systematic review, transparency of search strategy, panel composition, conflicts. Mandrola's critique and the committee's published rebuttal are the first time in a while a major U.S. guideline has had to defend its methodology in public. Whatever you think of the statin question, expect this template to get reused on the next guideline that expands a denominator.

Preventive cardiology's time horizon vs. geriatric time-to-benefit. A 30-year risk model and a 2.5-year time-to-benefit are pulling in opposite directions, and the collision point is your patient population. Nobody has yet written the rule for how a 30-year risk estimate should be discounted at 82 with CKD and six other medications — which means it lands on the admitting physician.

Oil's volatility is now a two-week cycle, not a two-month one. $100+ to $83 inside a week, entirely on diplomatic signal rather than physical supply. Thin buffers plus a drawn-down SPR mean any Hormuz headline moves the number 10%+ — and hurricane season is about to add a second variable on top.

E · Ideas & Opportunities

Order-set nudge worth ten minutes. Propose adding a "diarrhea ≥3 days" trigger to the ED and admission order sets that swaps plain O&P for a multiplex GI panel including Cyclospora. Two live outbreaks give you the strongest case you'll ever have for a change this small — bring the CDC numbers to the next group meeting.

A five-minute journal-club topic that will actually generate argument. Print the Mandrola critique and the committee's rebuttal side by side. It's short, it's readable, and it forces the room to articulate what a Class I recommendation is supposed to mean. Better than another negative-trial deck.

For the drive home: Man on the Run. McCartney doc, critics love it, and it's the rare thing you can queue up half-asleep and not lose the thread.